by Admin | Jul 30, 2025
Self-amplifying RNA (saRNA) is gaining momentum as the next frontier in RNA therapeutics and vaccine development. By integrating an RNA replicon system derived from alphaviruses, saRNA enables amplification of the target antigen in vivo, potentially reducing the...
by Admin | May 8, 2025
Supporting Innovation from Research to Clinical Manufacturing In the rapidly evolving field of RNA therapeutics, precise and efficient delivery remains a critical challenge—especially for systemic administration. At Areterna, we are helping solve this challenge by...
by Admin | Mar 24, 2025
As we step into 2025, we have entered the next era of RNA therapeutics. The global biotech and pharmaceutical industries are increasingly integrating mRNA-based medicines and the undeniable potential of RNA into their discovery and development pipelines. While the...
by Admin | Feb 20, 2025
The partnership between Synthgene Bio, BIORON, and Bion2 represents a major step toward global expansion, enhancing access to key resources for mRNA and oligo research and manufacturing in Eastern Europe. FOR IMMEDIATE RELEASE Gaithersburg, MD, USA and Römerberg,...
by Admin | Feb 1, 2025
Stay ahead in mRNA research and development with our newly available capped and uncapped reference standards! A linear mRNA molecule primarily consists of five components: the 5′ cap structure (5′ Cap), the 5′ untranslated region (5′ UTR), the...
